CHOP chemo plus mosunetuzumab for Richter's syndrome first treatment
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new immunotherapy drug (mosunetuzumab) combined with standard chemotherapy (CHOP) as the first treatment for Richter's syndrome, a fast-growing lymphoma that can arise from CLL. The goal is to see if this combination helps control the disease better than standard therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 79 years old.
- You have been diagnosed with Richter's syndrome (a type of aggressive lymphoma) that has not been treated yet.
- Your lymphoma cells have a protein called CD20 on their surface (a standard test will check this).
- You are physically active enough to care for yourself (ECOG score 0, 1, or 2).
- Your kidney, liver, and blood counts are within certain limits (your doctor will check these).
- You agree to use effective birth control if you or your partner could become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called glofitamab combined with standard chemo-immunotherapy (rituximab or obinutuzumab plus CHOP) for people with Richter syndrome, an aggressive lymphoma that arises from CLL. The goal is to see if the combination is safe and effective.
This trial tests a combination of two targeted drugs for people with Richter's transformation, an aggressive lymphoma that can develop from CLL. The goal is to see if this combination can help control the disease.
This trial tests a combination of four drugs for people whose chronic lymphocytic leukemia (CLL) has transformed into a more aggressive lymphoma called Richter syndrome. The goal is to see if this combination can control the cancer and improve outcomes.
This study tests a combination of two oral drugs (nemtabrutinib and pembrolizumab) for people with Richter transformation, an aggressive lymphoma that develops from chronic lymphocytic leukemia. It may be an option if standard chemotherapy is not suitable or if prior treatment has stopped working.
This study tests whether adding a targeted drug called pirtobrutinib to the usual chemotherapy for Richter transformation can improve outcomes. It is a phase 3 trial, meaning it compares the new combination to the standard approach, and may help patients live longer or delay progression.
This Phase 2 study tests zanubrutinib plus tislelizumab, with or without sonrotoclax, for people whose CLL has changed into Richter transformation (an aggressive lymphoma). It aims to improve anti-cancer response while tracking side effects and safety.
Hear when a new Richter Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.